Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.72 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9293406 | 0.91 | ADORA2B (0.83) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL16120984 | 0.90 | ADORA2B (0.81) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL8697228 | 0.89 | ADORA2B (0.81) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL4650753 | 0.89 | ADORA2B (0.79) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL9293800 | 0.88 | ADORA2B (0.78) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL9293922 | 0.88 | ADORA2B (0.78) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL9294488 | 0.88 | ADORA2B (0.78) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL8070551 | 0.88 | ADORA2B (0.78) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL10856641 | 0.88 | ADORA2B (0.78) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL10652746 | 0.88 | ADORA2B (0.78) | ADORA2BLMNAMAPTPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119595784-A | Method for detecting related substances of aminophylline injection | 山东玉满坤生物科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117169380-A | Aminophylline and method for detecting related substances or/and content of injection thereof | 湖南尔康制药股份有限公司 | 2023-12-05 | — | — | CN | claimed |
| US-20230008367-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2023-01-12 | — | — | US | claimed |
| EP-4034236-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | Abionyx Pharma SA (FR) | 2022-08-03 | — | — | EP | claimed |
| CN-114732842-A | Lightyellow sophora root extract with anti-tumor activity and quality detection method and application thereof | 南京中医药大学 | 2022-07-12 | — | — | CN | claimed |
| CN-114558059-A | Radix sophorae flavescentis-coptis chinensis extract with anti-tumor activity and quality detection method and application thereof | 南京中医药大学 | 2022-05-31 | — | — | CN | claimed |
| CN-114555614-A | Anti-cancer compounds as non-PGP substrates | 深圳艾欣达伟医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-114223448-A | Planting method for phyllostachys pubescens | 湖南绿地高新农林开发有限公司 | 2022-03-25 | — | — | CN | claimed |
| WO-2021059023-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2021-04-01 | — | — | WO | claimed |
| US-5151273-A | Time release tablets or dragees made from hemicelluloses, adjuvants of a copolymer of hydroxybutyric acid and hydroxyvaleric acid | LENZING AKTIENGESELLSCHAFT (AT) | 1992-09-29 | — | — | US | claimed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | claimed |
| EP-0480934-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION. | DAK LAB AS (DK) | 1992-04-22 | — | — | EP | claimed |
| WO-1991000730-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION | DAK-LABORATORIET A/S (DK) | 1991-01-24 | — | — | WO | claimed |
| US-4902516-A | WITH COATING OF POLY-3-HYDROXYBUTYROLACTONE; DRUG DELIVERY | CHEMIE HOLDING AKTIENGESELLSCHAFT (AT) | 1990-02-20 | — | — | US | claimed |
| US-4844910-A | CONTROLLED RELEASE OF THEOPHYLLINE DERIVATIVES | EUROCELTIQUE, S.A. (LU) | 1989-07-04 | — | — | US | claimed |
| EP-0270305-A2 | Spheroids | Euroceltique S.A. (LU) | 1988-06-08 | — | — | EP | claimed |
| EP-0191624-A2 | Gold-purine antitumor agents | ENGELHARD CORPORATION (US) | 1986-08-20 | — | — | EP | claimed |
| US-4606920-A | ETOFYLLINE, VITAMIN A, AND MAGNESIUM COMPOUND | WALTER HANS PETER (DE) | 1986-08-19 | — | — | US | claimed |
| EP-0059974-B1 | PROCESS FOR THE PREPARATION OF PHENOXYALCANECARBONIC-ACID ESTERS OF HYDROXYETHYL THEOPHYLINE | Ludwig Merckle GmbH & Co. chem.-pharm. Fabrik (DE) | 1985-07-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008367-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | SLC10A1, CPT1A, CES1 | ADORA2B 1780/4885LMNA 2355/4885MAPT 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.